Header Logo

Connection

Paul Hesketh to Adult

Back to Details
This is a "connection" page, showing publications Paul Hesketh has written about Adult.
Paul Hesketh
Connection Strength
0.509
Adult
  1. Hesketh PJ, Palmas M, Nicolas P. Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic. Support Care Cancer. 2018 Apr; 26(4):1151-1159.
    View in: PubMed
    Score: 0.042
  2. Hesketh PJ, Schnadig ID, Schwartzberg LS, Modiano MR, Jordan K, Arora S, Powers D, Aapro M. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer. 2016 Aug 01; 122(15):2418-25.
    View in: PubMed
    Score: 0.038
  3. Hesketh PJ, Bosnjak SM, Nikolic V, Rapoport B. Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. Support Care Cancer. 2011 Dec; 19(12):2063-6.
    View in: PubMed
    Score: 0.028
  4. Hesketh PJ, Sanz-Altamira P. Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting. Support Care Cancer. 2012 Mar; 20(3):653-6.
    View in: PubMed
    Score: 0.028
  5. Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer. 2012 May; 20(5):1043-7.
    View in: PubMed
    Score: 0.027
  6. Hesketh PJ, Younger J, Sanz-Altamira P, Hayden M, Bushey J, Trainor B, Krentzin M, Nowd P, Arnaoutakis K, Hesketh AM. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer. 2009 Aug; 17(8):1065-70.
    View in: PubMed
    Score: 0.023
  7. Hesketh PJ, Chansky K, Israel V, Grapski RT, Mekhail TM, Spiridonidis CH, Mills GM, Kelly K, Crowley JJ, Gandara DR. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718. J Thorac Oncol. 2007 May; 2(5):440-4.
    View in: PubMed
    Score: 0.020
  8. Hesketh PJ, McCoy J, Dunphy FR, Bearden JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. J Thorac Oncol. 2006 Nov; 1(9):991-5.
    View in: PubMed
    Score: 0.020
  9. Oo TH, Aish LS, Schneider D, Hesketh PJ. Uncommon hematologic malignancies. Case 2. Calcification in untreated primary mediastinal large B-cell lymphoma with sclerosis. J Clin Oncol. 2003 Nov 15; 21(22):4249-51.
    View in: PubMed
    Score: 0.016
  10. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003 Nov 15; 21(22):4112-9.
    View in: PubMed
    Score: 0.016
  11. Ballen KK, Hesketh AM, Heyes C, Becker PS, Emmons RV, Fogarty K, LaPointe J, Liu Q, Hsieh CC, Hesketh PJ. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant. 2001 Dec; 28(11):1061-6.
    View in: PubMed
    Score: 0.014
  12. Hesketh PJ, Crews JR, Cohen R, Blackburn LM, Friedman CJ. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy. Cancer J. 2000 May-Jun; 6(3):157-61.
    View in: PubMed
    Score: 0.013
  13. Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen. Support Care Cancer. 2000 Jan; 8(1):46-8.
    View in: PubMed
    Score: 0.012
  14. Hesketh PJ, Crowley JJ, Burris HA, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF, Livingston RB, Gandara DR. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am. 1999 Jul-Aug; 5(4):237-41.
    View in: PubMed
    Score: 0.012
  15. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, Silberman SL. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol. 1999 Jan; 17(1):338-43.
    View in: PubMed
    Score: 0.011
  16. Goldberg ME, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, Giaccone G, Akerley WL, Dowlati A, Creelan BC, Hicks JK, Hesketh PJ, Kelly KL, Riess JW, Miller VA, Stephens PJ, Frampton GM, Ali S, Gregg JP, Albacker LA. Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS One. 2018; 13(11):e0208097.
    View in: PubMed
    Score: 0.011
  17. Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst. 1997 Jun 04; 89(11):817-8.
    View in: PubMed
    Score: 0.010
  18. Hesketh PJ, Gandara DR, Hesketh AM, Edelman M, Webber LM, McManus M, Hainsworth JD. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone. Cancer J Sci Am. 1997 May-Jun; 3(3):180-3.
    View in: PubMed
    Score: 0.010
  19. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol. 1996 Aug; 14(8):2242-9.
    View in: PubMed
    Score: 0.010
  20. Aapro M, Hesketh PJ, Jordan K, Gralla RJ, Rossi G, Rizzi G, Palmas M. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program. Oncologist. 2016 Apr; 21(4):494-502.
    View in: PubMed
    Score: 0.009
  21. Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, Martin LA, Cramer MB, Hahne WF. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer. 1996 Mar; 4(2):141-6.
    View in: PubMed
    Score: 0.009
  22. Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016 Apr; 24(4):1517-25.
    View in: PubMed
    Score: 0.009
  23. Hesketh PJ, Beck T, Uhlenhopp M, Kris MG, Hainsworth JD, Harker WG, Cohen JR, Lester E, Kessler JF, Griffen D, et al. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol. 1995 Aug; 13(8):2117-22.
    View in: PubMed
    Score: 0.009
  24. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol. 1994 Mar; 12(3):596-600.
    View in: PubMed
    Score: 0.008
  25. Hesketh PJ, Tansan S, Caguioa PB, Hesketh A, Blanchard R, DiMartino N, Carney D. Treatment of advanced non-small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C. Cancer. 1993 Feb 01; 71(3):717-20.
    View in: PubMed
    Score: 0.008
  26. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ. Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer. 1993; 29A Suppl 1:S35-8.
    View in: PubMed
    Score: 0.008
  27. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, Finn AL, Hesketh PJ. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol. 1992 Aug; 19(4 Suppl 10):67-71.
    View in: PubMed
    Score: 0.007
  28. Sangha R, Davies AM, Lara PN, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9.
    View in: PubMed
    Score: 0.007
  29. Hesketh PJ, Clapp RW, Doos WG, Spechler SJ. The increasing frequency of adenocarcinoma of the esophagus. Cancer. 1989 Jul 15; 64(2):526-30.
    View in: PubMed
    Score: 0.006
  30. Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol. 1989 Jun; 7(6):700-5.
    View in: PubMed
    Score: 0.006
  31. Hesketh PJ, Cooley TP, Finkel HE, Wright J, Hesketh AM. Treatment of advanced non-small cell lung cancer with cisplatin, 5-fluorouracil, and mitomycin C. Cancer. 1988 Oct 15; 62(8):1466-70.
    View in: PubMed
    Score: 0.006
  32. Hesketh PJ. Evaluation and treatment of testicular cancer. Hosp Pract (Off Ed). 1987 Sep 30; 22(9A):87-90, 93-102.
    View in: PubMed
    Score: 0.005
  33. Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara DR. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol. 2007 Jun; 2(6):526-30.
    View in: PubMed
    Score: 0.005
  34. Davies AM, Ho C, Hesketh PJ, Beckett LA, Lara PN, Lau DH, Gandara DR. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Invest New Drugs. 2007 Aug; 25(4):351-5.
    View in: PubMed
    Score: 0.005
  35. Hesketh PJ, McCaffrey RP, Finkel HE, Larmon SS, Griffing GT, Melby JC. Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep. 1987 Feb; 71(2):222-4.
    View in: PubMed
    Score: 0.005
  36. Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005 Jun; 41(9):1278-85.
    View in: PubMed
    Score: 0.004
  37. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005 Apr 20; 23(12):2822-30.
    View in: PubMed
    Score: 0.004
  38. Safran H, Gaissert H, Akerman P, Hesketh PJ, Chen MH, Moore T, Koness J, Graziano S, Wanebo HJ. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest. 2001; 19(1):1-7.
    View in: PubMed
    Score: 0.003
  39. Safran H, Akerman P, Cioffi W, Gaissert H, Joseph P, King T, Hesketh PJ, Wanebo H. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):53-7.
    View in: PubMed
    Score: 0.003
  40. Whitmore JB, Kris MG, Hesketh PJ, Grote TH, DuBois DM, Cramer MB, Hahne WF. Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials. Support Care Cancer. 1998 Sep; 6(5):473-8.
    View in: PubMed
    Score: 0.003
  41. Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W, Friedman C. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998 Apr; 16(4):1568-73.
    View in: PubMed
    Score: 0.003
  42. Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998 Feb; 16(2):754-60.
    View in: PubMed
    Score: 0.003
  43. Safran H, King TP, Choy H, Hesketh PJ, Wolf B, Altenhein E, Sikov W, Rosmarin A, Akerley W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo HJ. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin Oncol. 1997 Mar; 15(3):901-7.
    View in: PubMed
    Score: 0.003
  44. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May; 13(5):1242-8.
    View in: PubMed
    Score: 0.002
  45. Tansan S, Emri S, Sel?uk T, Ko? Y, Hesketh P, Heeren T, McCaffrey RP, Baris YI. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology. 1994 Jul-Aug; 51(4):348-51.
    View in: PubMed
    Score: 0.002
  46. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992 Dec; 10(12):1969-75.
    View in: PubMed
    Score: 0.002
  47. Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, Gandara D, Hesketh P, Khojasteh A, Harker G, et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol. 1991 May; 9(5):721-8.
    View in: PubMed
    Score: 0.002
  48. Bulger KN, Hesketh PJ, Babayan RK. Discordant human chorionic gonadotropin results giving rise to inappropriate therapy in a case of testicular cancer. J Urol. 1989 Dec; 142(6):1574-5.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.